Supplemental Disclosures (Tables)

3 Months Ended

Mar. 31, 2025

Payables and Accruals [Abstract]

Schedule of Other Current Assets

Other current assets consisted of the following (in thousands):

	March 31, 2025		December 31, 2024
Net cost reimbursement due from AbbVie	$	14,082	$	11,304
Accrued interest on investments		965		1,094
Other		1,035		1,376
	$	16,082	$	13,774

Schedules of Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):

	March 31, 2025		December 31, 2024
Accrued personnel costs	$	8,534	$	17,607
Accrued external research and development expenses		6,332		8,998
Accrued sublicense fees and royalties		6,183		8,658
Accrued external general and administrative expenses		1,734		2,002
Accrued purchases of property and equipment		35		156
Other		779		649
	$	23,597	$	38,070